INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Healthy Aging & Longevity desk →

930 studies · page 29 of 39

2025 / Randomized controlled trial (2x2 factorial)

Neither cocoa extract nor multivitamin/multimineral supplementation reduced incident fracture risk in older adults.

In an ancillary study to the COSMOS trial, 21,442 older adults were randomized to receive daily cocoa extract (500 mg/d flavanols, 80 mg/d (-)-epicatechin), a daily multivitamin/multimineral (MVM; Centrum Silver), both, or placebos for a median of 3.6 years. During follow-up, 2,083 incident clinical fractures occurred. Compared with placebo, cocoa extract did not significantly reduce the risk of incident clinical fracture (aHR 1.03, 95% CI 0.95-1.12) or nonvertebral fracture (aHR 1.05, 95% CI 0.96-1.14). Similarly, MVM supplementation was not associated with lower risk of total clinical fracture (aHR 1.09, 95% CI 1.00-1.19), hip fracture (aHR 1.06, 95% CI 0.80-1.42), or nonvertebral fracture (aHR 1.10, 95% CI 1.00-1.20).

Crandall CJ, Chou S, Kim E, et al. J Bone Miner Res, 2025. PMID 39964350

2025 / Double-blind, placebo-controlled, 2x2 factorial randomized trial

Cocoa flavanol supplementation for a median of 3.6 years did not significantly reduce the overall risk of AMD in older adults.

As an ancillary study of the COSMOS trial, 21,442 older US adults were randomized to receive a daily cocoa extract supplement (500 mg/day flavanols, including 80 mg (-)-epicatechin) or placebo. Over a median of 3.6 years, 344 participants experienced a confirmed AMD event. There were 159 cases (1.5%) in the cocoa extract group compared to 185 cases (1.7%) in the placebo group, showing no significant overall effect (HR, 0.87; 95% CI, 0.71-1.08; P = .21). Due to nonproportional hazards, separate models suggested a reduced risk during the first 2 years (HR, 0.77; 95% CI, 0.59-1.01) but no benefit beyond 2 years (HR, 1.06; 95% CI, 0.76-1.50).

Christen WG, Rist PM, Moorthy MV, et al. JAMA Ophthalmol, 2025. PMID 40146119

2024 / Multicenter randomized controlled trial

A 20-week intensive multidomain lifestyle intervention improved cognition, function, and biomarkers in patients with MCI or early AD dementia.

A 1:1 randomized controlled trial evaluated the effects of a 20-week intensive multidomain lifestyle intervention versus a wait-list usual care control group in 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease. After 20 weeks, significant between-group differences favored the intervention group in CGIC (p = 0.001), CDR-SB (p = 0.032), and CDR Global (p = 0.037), with borderline significance for ADAS-Cog (p = 0.053). The intervention group improved on CGIC, CDR Global, and ADAS-Cog and had significantly less progression on CDR-SB, while the control group worsened on all four measures. Plasma Aβ42/40 ratio increased in the intervention group and decreased in controls (p = 0.003), and the microbiome improved only in the intervention group (p < 0.0001).

Ornish D, Madison C, Kivipelto M, et al. Alzheimers Res Ther, 2024. PMID 38849944

2023 / Randomized controlled trial

A low-fat vegan diet with daily soybeans reduced moderate-to-severe hot flashes by 88% in postmenopausal women.

Postmenopausal women were randomized to a 12-week intervention including a low-fat, vegan diet and cooked soybeans (1/2 cup [86 g] daily) or a control group with no dietary changes. In the intervention group, moderate-to-severe hot flashes decreased by 88% compared to 34% in the control group (between-group P < 0.001). At 12 weeks, 50% of completers in the intervention group reported no moderate-to-severe hot flashes, compared to no change from baseline among controls (P < 0.001). The intervention group also experienced greater reductions in vasomotor (P = 0.004), physical (P = 0.01), and sexual (P = 0.03) domains of quality of life, with improvements independent of equol production status or seasonality.

Barnard ND, Kahleova H, Holtz DN, et al. Menopause, 2023. PMID 36253903

2023 / Randomized, double-blind, placebo-controlled 3-arm comparative trial

CurQfen-curcumin supplementation improved cognitive scores, locomotor function, and related biomarkers in subjects with moderate Alzheimer's dementia.

A 6-month randomized, double-blind, placebo-controlled study evaluated 48 subjects with moderate Alzheimer's disease dementia assigned to 400 mg twice daily of placebo, unformulated standard curcumin complex, or bioavailable CurQfen-curcumin (CGM). Supplementation with CGM led to significant improvements (P < 0.05) in Mini-Mental State Examination (MMSE) and Geriatric Locomotive Function Scale (GLFS) scores in both intra- and inter-group comparisons. Analysis of serum biomarkers (BDNF, Aβ42, tau protein, IL-6, and TNF-α) also demonstrated significant improvement (P < 0.05) in the CGM group compared to both placebo and unformulated curcumin.

Das SS, Gopal PM, Thomas JV, et al. Front Dement, 2023. PMID 39081970

2022 / Randomized, double-blind, placebo-controlled study

Afternoon intake of nicotinamide mononucleotide improved lower limb function and reduced drowsiness in older adults.

A randomized, double-blind, placebo-controlled study evaluated the effects of 250 mg daily nicotinamide mononucleotide (NMN) taken in the morning (AM) or afternoon (PM) for 12 weeks among 108 older adults across four groups. Five-times sit-to-stand (5-STS) improved post-intervention in all groups, while drowsiness improved at mid- and post-intervention in the NMN_PM and Placebo_PM groups. The NMN_PM group exhibited the largest effect sizes for 5-STS (d = 0.72) and drowsiness (d = 0.64). Overall, afternoon NMN intake effectively improved lower limb function and reduced drowsiness.

Kim M, Seol J, Sato T, et al. Nutrients, 2022. PMID 35215405

2022 / Double-blind randomized phase I clinical trial

Nicotinamide riboside supplementation was well tolerated and increased cerebral NAD levels in patients with Parkinson's disease.

A double-blind phase I trial evaluated oral nicotinamide riboside (NR; 1,000 mg daily) versus placebo for 30 days in 30 newly diagnosed, treatment-naive Parkinson's disease patients. NR was well tolerated and caused a significant, though variable, increase in cerebral NAD levels and related CSF metabolites. Patients with increased brain NAD levels showed altered cerebral metabolism that was linked to mild clinical improvement. NR also upregulated processes linked to mitochondrial, lysosomal, and proteasomal function in blood and/or muscle, and lowered inflammatory cytokines in serum and CSF.

Brakedal B, Dölle C, Riemer F, et al. Cell Metab, 2022. PMID 35235774

2022 / Placebo-controlled, randomized, double-blind, parallel-group trial

Oral administration of 250 mg/day of nicotinamide mononucleotide for 12 weeks was safe and significantly increased whole blood NAD+ levels in healthy subjects.

In a randomized, double-blind trial, 30 healthy volunteers received either 250 mg/day of NMN (n = 15) or a placebo (n = 15) for 12 weeks. Oral NMN caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed. Whole blood NAD+ and nicotinic acid mononucleotide (NAMN) levels were significantly increased after NMN administration, while NMN levels themselves were not. Additionally, the increase in NAD+ was strongly correlated with pulse rate prior to NMN administration.

Okabe K, Yaku K, Uchida Y, et al. Front Nutr, 2022. PMID 35479740

2021 / Randomized, double-blind, placebo-controlled crossover trial

Resveratrol supplementation improved cognitive performance, cerebrovascular function, and insulin sensitivity in postmenopausal women.

In a 24-month crossover trial, 125 postmenopausal women aged 45-85 years took 75 mg trans-resveratrol or placebo twice daily for 12 months, followed by the alternative treatment for 12 months. Compared to placebo, resveratrol resulted in a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Resveratrol also improved resting mean cerebral blood flow velocity (d = 0.275, P = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, P = 0.027) and cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025), and insulin resistance index (d = 0.102, P = 0.034). Women aged 65 and older showed a relative improvement in verbal memory compared to those younger than 65 years.

Thaung Zaw JJ, Howe PR, Wong RH Clin Nutr, 2021. PMID 32900519

2021 / Randomized, double-blind, crossover trial

Anthocyanin-rich plum juice improved postprandial vascular function and reduced C-reactive protein after a high-fat high-energy meal in overweight older adults.

Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.

do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012

2021 / Multicenter randomized controlled trial

Daily n-3 fatty acid supplementation did not reduce cardiovascular events in elderly patients with recent myocardial infarction.

The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.

Kalstad AA, Myhre PL, Laake K, et al. Circulation, 2021. PMID 33191772

2021 / Prospective randomised double-blind sham-controlled study

Whole-body cryotherapy improved immediate recall, orientation, and mood measures in participants with mild cognitive impairment.

In a prospective randomised double-blind sham-controlled trial, 62 participants with mild cognitive impairment were allocated to whole-body cryotherapy (-110 °C to -160 °C; n = 33) or a placebo control group (n = 29). After the 10th session (T2), significant differences favored the cryotherapy group in immediate recall (DemTect) and orientation (TYM). Improvements in mood were detected in self-reported depressive symptoms (T2 p = 0.04; VAS mood T2 p = 0.02; T3 p = 0.07), alongside a significant reduction in BDNF level (p < 0.05).

Rymaszewska J, Lion KM, Stańczykiewicz B, et al. Exp Gerontol, 2021. PMID 33454354

2021 / Randomized controlled trial

Daily almond intake increased minimal erythema dose to UVB radiation compared to pretzels in healthy Asian women.

A randomized trial investigated whether daily oral almond consumption increases UVB resistance and reduces skin aging in 39 healthy Asian women (18-45 years, Fitzpatrick skin type II-IV). Participants consumed either 1.5 oz of almonds or 1.8 oz of pretzels daily for 12 weeks. The minimal erythema dose (MED) increased in the almond group compared to the pretzel group. No differences were observed between groups in facial Allergan roughness, melanin, hydration, or sebum.

Li JN, Henning SM, Thames G, et al. J Cosmet Dermatol, 2021. PMID 33491323

2021 / Randomized controlled trial

In healthy older adults, protein supplementation alone did not improve muscle size or strength, but heavy resistance training with whey protein did.

In a 1-year randomized controlled trial, 208 healthy older adults were assigned to carbohydrate (CARB), collagen (COLL), whey protein (WHEY), light resistance training plus whey (LITW), or heavy resistance training plus whey (HRTW). COLL and WHEY alone did not affect any measured parameter compared to CARB. Compared to WHEY, HRTW increased quadriceps cross-sectional area (+1.68 cm2; 95% CI: +0.41 to +2.95 cm2; P = 0.03), dynamic strength (+18.4 Nm; P < 10-4), and isometric strength (+23.9 Nm; P < 10-5), while LITW improved dynamic knee extensor strength (+13.7 Nm; P = 0.01) without improving muscle size.

NANO counterpoint →

Mertz KH, Reitelseder S, Bechshoeft R, et al. Am J Clin Nutr, 2021. PMID 33564844

2021 / Randomized, double-blind, controlled trial

Supplementation with NAD+ precursors for 32 days did not improve mitochondrial or skeletal muscle function in physically compromised older adults.

A randomized, double-blind, controlled trial evaluated the effects of 32 days of NAD+-precursor supplementation (207.5 mg niacin equivalents/day from tryptophan, nicotinic acid, and nicotinamide) versus control in 14 older adults with impaired physical function. Skeletal muscle NAD+ concentrations were not significantly different between intervention and control (7.5 ± 1.9 vs 7.9 ± 1.6 AU), although methyl-nicotinamide levels were significantly higher (0.098 ± 0.063 vs 0.025 ± 0.014; P = 0.001). Neither ADP-stimulated mitochondrial respiration (82.1 ± 19.0 vs 84.0 ± 19.2; P = 0.716), maximally uncoupled mitochondrial respiration (103.4 ± 30.7 vs 108.7 ± 33.4; P = 0.495), nor net exercise efficiency (20.2 ± 2.77 vs 20.8 ± 2.88; P = 0.342) improved with supplementation.

Connell NJ, Grevendonk L, Fealy CE, et al. J Nutr, 2021. PMID 34191033

2021 / Randomized controlled trial

A low-fat vegan diet with daily cooked soybeans significantly reduced the frequency and severity of hot flashes in postmenopausal women.

Postmenopausal women were randomly assigned to a low-fat, vegan diet including 1/2 cup (86 g) of cooked soybeans daily, or to no diet changes for 12 weeks. Total hot flashes decreased 79% in the intervention group compared to 49% in controls (between-group P = 0.01), and moderate-to-severe hot flashes decreased 84% versus 42% (between-group P = 0.01). Furthermore, 59% (10/17) of the intervention group became free of moderate and severe hot flashes, while the control group saw no change (between-group P < 0.001). Significantly greater improvements were also observed in the intervention group across vasomotor, psychosocial, physical, and sexual quality of life domains.

Barnard ND, Kahleova H, Holtz DN, et al. Menopause, 2021. PMID 34260478

2021 / 16-week, double-blind, randomized, placebo-controlled trial

In pre-frail and frail older adults, protein, leucine, or creatine supplements did not enhance the benefits of resistance training on muscle mass or function.

A 16-week, double-blind, randomized, placebo-controlled trial investigated whether nutritional supplements enhance adaptations to twice-weekly resistance training in 200 pre-frail and frail elderly individuals. Across four sub-investigations, leucine supplementation was ineffective for improving muscle mass and function, and whey, soy, or creatine (alone or combined) failed to enhance resistance training adaptations. Furthermore, no sex-based differences were observed in response to whey. Resistance exercise alone increased muscle mass and function in all sub-investigations, and no adverse effects were reported.

Roschel H, Hayashi AP, Fernandes AL, et al. Clin Nutr, 2021. PMID 34358827

2021 / Randomized, double-blind, placebo-controlled trial

In mild to moderate Alzheimer's disease, 52 weeks of trans-resveratrol decreased CSF MMP-9 by 46% and reduced brain volume compared to placebo.

Thirty patients with moderate to mild Alzheimer's disease were randomized to receive 500 mg trans-resveratrol orally once daily or placebo for 52 weeks. Trans-resveratrol did not lead to statistically significant changes in blood or CSF Aβ40, whereas placebo participants showed significant decreases in CSF (P = 0.024) and plasma Aβ40 (P = 0.036). Compared with placebo, trans-resveratrol resulted in a significant reduction in brain volume at 52 weeks (P = 0.011) and a 46% decrease in CSF matrix metallopeptidase 9 (P = 0.033).

Gu J, Li Z, Chen H, et al. Neurol Ther, 2021. PMID 34402024

2020 / Staggered multiple baseline intervention trial

A community-delivered exercise and behavioral intervention improved physical activity and quality of life in persons with dementia and caregiver depression.

A 6-week in-home multicomponent program combining exercise with behavioral/psychosocial training was translated into community delivery by Area Agencies on Aging case managers. Among 255 enrolled dyads, 207 completed the intervention and 140 completed a 13-month follow-up. Persons with dementia had significant increases in physical activity from pre- to posttreatment (p < .001, ES = .54) and at 13 months (p < .01, ES = .21), as well as increased quality of life pre- to posttreatment (p < .001, ES = .29). Caregiver depression also improved from pre- to posttreatment (p = .01, ES = -.18).

Teri L, Logsdon RG, McCurry SM, et al. Gerontologist, 2020. PMID 30304477

2020 / Double-blind cross-over trial

Acute nicotinamide riboside supplementation improved redox markers and specific exercise performance outcomes in older, but not younger, men.

Twelve young and twelve old men received acute nicotinamide riboside (NR) or placebo in a double-blind cross-over study. NR supplementation increased NADH (51% young; 59% old) and NADPH (32% young; 38% old) in both groups, but only in older men did it decrease urine F2-isoprostanes by 18% (P < 0.05) and tend to raise glutathione (P = 0.078). In older individuals, NR improved isometric peak torque by 8% (P = 0.048) and the fatigue index by 15% (P = 0.012), while having no effect on VO2max, concentric peak torque, or physiological performance in young men.

Dolopikou CF, Kourtzidis IA, Margaritelis NV, et al. Eur J Nutr, 2020. PMID 30725213

2020 / Single-arm non-randomized trial

Single oral administration of up to 500 mg NMN was safe and effectively metabolized without significant deleterious effects in healthy men.

Ten healthy men received single oral doses of 100, 250, and 500 mg nicotinamide mononucleotide (NMN), with clinical parameters and NMN metabolite pharmacokinetics monitored for 5 hours after each intervention. The single oral doses caused no significant clinical symptoms or changes in heart rate, blood pressure, oxygen saturation, body temperature, ophthalmic examination, or sleep quality. Laboratory analyses showed increases in serum bilirubin and decreases in serum creatinine, chloride, and blood glucose within normal ranges, independent of dose. Plasma concentrations of N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide increased significantly in a dose-dependent manner.

Irie J, Inagaki E, Fujita M, et al. Endocr J, 2020. PMID 31685720

2020 / 12-month double-blind randomized controlled trial

Whey-enriched protein supplementation did not improve physical performance or muscle measures in older adults with sarcopenia.

A 12-month randomized controlled trial evaluated 20 g twice daily whey-enriched protein supplementation versus an isocaloric placebo and a no-supplement control in 218 older people with sarcopenia, with all given instructions on home-based exercise, dietary protein, and vitamin D (20 μg/d). The supplements had no significant effect on physical performance; 12-month changes in short physical performance battery scores were -0.55, -0.05, and 0.03 points across control, isocaloric, and protein groups (P = .17), with similar changes in continuous summary physical performance scores (P = .76). Hand grip strength decreased significantly in all groups, calf muscle index showed no differences between groups, and post-trial follow-up found no differences in all-cause mortality or physical functioning. Mild gastrointestinal adverse effects were reported by 56% in both supplement groups.

Björkman MP, Suominen MH, Kautiainen H, et al. J Am Med Dir Assoc, 2020. PMID 31734121

1988 / Review

A review discusses evidence linking environmental aluminum to Alzheimer disease and certain encephalopathies.

This article discusses the possible involvement of environmental aluminum in the etiology of Alzheimer disease and senile dementia of the Alzheimer type. The hypothesis is supported by direct and indirect relationships between certain encephalopathies and the abnormal presence of aluminum(III) in human and animal brain tissues. Proposals for further biochemical, toxicological, and analytical work are illustrated.

Shows an association, not proof of cause and effect.

Zatta P, Giordano R, Corain B, et al. Med Hypotheses, 1988. PMID 3412205

1982 / Narrative review / geographic analysis

A review explores the hypothesis that long-term milk intake and high lactase activity may increase the likelihood of developing senile cataracts.

This article examines evidence regarding the hypothesis that decades-long consumption of milk and dairy products may contribute to certain senile cataracts. It approaches the topic through the geography and history of dairying and global differences in adult lactose malabsorption. Populations with long histories of consuming lactose-rich milk developed persistence of high lactase activity throughout life (PHLA), allowing greater galactose absorption without a corresponding increase in galactokinase activity. The author suggests this may lead to repeated galactose challenges, accumulation of galactitol in the lens, and an increased likelihood of senile cataracts.

Shows an association, not proof of cause and effect.

Simoons FJ Dig Dis Sci, 1982. PMID 6804198